Van ECK Associates Corp Sells 119,848 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Van ECK Associates Corp lessened its holdings in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 34.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 223,420 shares of the company's stock after selling 119,848 shares during the period. Van ECK Associates Corp owned 0.06% of Bausch Health Companies worth $1,801,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Tobam lifted its holdings in Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after purchasing an additional 1,422 shares during the last quarter. DGS Capital Management LLC bought a new stake in Bausch Health Companies in the 4th quarter valued at $143,000. Merit Financial Group LLC acquired a new position in Bausch Health Companies in the fourth quarter worth about $228,000. Sanders Morris Harris LLC lifted its position in shares of Bausch Health Companies by 16.0% during the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after buying an additional 4,000 shares during the period. Finally, Northwest & Ethical Investments L.P. lifted its holdings in shares of Bausch Health Companies by 13.0% during the third quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company's stock valued at $264,000 after acquiring an additional 3,734 shares during the period. Institutional investors own 78.65% of the company's stock.

Analyst Upgrades and Downgrades

BHC has been the subject of several recent analyst reports. Royal Bank of Canada dropped their price objective on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th. Jefferies Financial Group restated a "hold" rating and set a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Bausch Health Companies currently has an average rating of "Hold" and a consensus price target of $7.42.

Remove Ads

Bausch Health Companies Stock Up 5.4 %

NYSE BHC traded up $0.39 during trading on Tuesday, reaching $7.56. 2,919,658 shares of the stock traded hands, compared to its average volume of 3,369,091. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of -62.95, a price-to-earnings-growth ratio of 0.37 and a beta of 0.68. The stock's 50-day moving average price is $7.34 and its 200 day moving average price is $7.54.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. Analysts anticipate that Bausch Health Companies Inc. will post 4.41 EPS for the current fiscal year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.